Rocket Pharmaceuticals, Inc.

RCKT

US77313F1066

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 05/07/2024 BST			5-day change	1st Jan Change
19.96 ^USD	-0.35%		-7.29%	-33.40%

07-03	Canaccord Genuity Adjusts Price Target on Rocket Pharmaceuticals to $40 From $49, Maintains Buy Rating	MT
07-01	Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 3000 Value Index	CI

Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell Small Cap Comp Value Index

July 30, 2024

Latest news about Rocket Pharmaceuticals, Inc.

Canaccord Genuity Adjusts Price Target on Rocket Pharmaceuticals to $40 From $49, Maintains Buy Rating	07-03	MT
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 3000 Value Index	06-30	CI
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 2500 Value Index	06-30	CI
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell Small Cap Comp Value Index	06-30	CI
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 2000 Value Index	06-30	CI
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 3000E Value Index	06-30	CI
Needham Trims Price Target on Rocket Pharmaceuticals to $52 From $53, Maintains Buy Rating	06-28	MT
Rocket Pharmaceuticals Says FDA Seeks More Information on Kresladi	06-28	MT
Rocket Pharmaceuticals Shares Slide After FDA Rejects Kresladi	06-28	DJ
FDA Turns Away Rocket Pharma's Gene Therapy, Seeks More Data	06-28	DJ
US FDA declines to approve Rocket Pharma's immune disorder gene therapy	06-28	RE
Rocket Pharmaceuticals, Inc. Provides Regulatory Update on KRESLADI? (marnetegragene autotemcel; marne-cel)	06-28	CI
Rocket Pharmaceuticals' Gene Therapy for Inherited Heart Disease Receives Orphan Drug Designation in Europe	05-29	MT
Transcript : Rocket Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM	05-16
UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating	05-10	MT
Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise	05-10	MT
Rocket Pharmaceuticals Presents Positive Data from Lv Hematology Portfolio At the 27Th Annual Meeting of the American Society of Gene and Cell Therapy	05-10	CI
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	04-16	MT
Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	04-11	MT
Rocket Pharmaceuticals Says European Medicines Agency Accepted Marketing Authorization Application for RP-L102	04-02	MT
Goldman Sachs Initiates Rocket Pharmaceuticals at Neutral With $39 Price Target	04-02	MT
Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	04-02	CI
Rocket Pharmaceuticals Appoints Aaron Ondrey as CFO	03-26	MT
Rocket Pharmaceuticals, Inc. Announces Appointment of Aaron Ondrey as Chief Financial Officer	03-26	CI

Chart Rocket Pharmaceuticals, Inc.

Duration

Period

More charts

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

19.96 USD

Average target price

48.92 USD

Spread / Average Target

+145.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ROCKET PHARMACEUTICALS, INC.	-33.40%	1.81B
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs